Targeted therapy of spontaneous murine pancreatic tumors by polymeric micelles prolongs survival and prevents peritoneal metastasis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 28, 2013, Pages 11397-11402

  Cabral, Horacio ^a   Murakami, Mami ^a   Hojo, Hironori ^b   Terada, Yasuko ^c   Kano, Mitsunobu R ^d   Chung, Ung Il ^a,b   Nishiyama, Nobuhiro ^e   Kataoka, Kazunori ^a,b  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c JAPAN SYNCHROTRON RADIATION RESEARCH INSTITUTE   (Japan)

^d OKAYAMA UNIVERSITY   (Japan)

^e TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

(1,2 Diaminocyclohexane)platinum(II); Chemotherapy; Drug delivery

Indexed keywords

( 1,2 DIAMINOCYCLOHEXANE)PLATINUM NITRATE CHLORIDE; ANTINEOPLASTIC METAL COMPLEX; CA 19-9 ANTIGEN; COPOLYMER; LUCIFERASE; MACROGOL; NANOCARRIER; OXALIPLATIN; PANCREATIC ELASTASE; POLYGLUTAMIC ACID; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG TUMOR LEVEL; IC 50; MALE; MICELLE; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PERITONEUM METASTASIS; PHOTON; PRIORITY JOURNAL; SIMIAN VIRUS 40; SURVIVAL TIME; TRANSGENIC MOUSE;

(1,2-DIAMINOCYCLOHEXANE)PLATINUM(II); CHEMOTHERAPY; DRUG DELIVERY;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG CARRIERS; MICE; MICELLES; PANCREATIC NEOPLASMS; PERITONEAL NEOPLASMS; SURVIVAL ANALYSIS;

MURINAE; MUS; MUS MUSCULUS; SIMIAN VIRUS 40;

EID: 84879915420     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1301348110     Document Type: Article

References (52)

1. Heidel JD, Davis ME (2011) Clinical developments in nanotechnology for cancer therapy. Pharm Res 28(2):187-199.
2. Peer D, et al. (2007) Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2(12):751-760. (Pubitemid 350223348)
3. Duncan R (2006) Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 6(9):688-701.
4. Miyata K, Christie RJ, Kataoka K (2011) Polymeric micelles for nano-scale drug delivery. React Funct Polym 7(3):227-234.
5. Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46(12 Pt 1):6387-6392. (Pubitemid 17221789)
6. Frese KK, Tuveson DA (2007) Maximizing mouse cancer models. Nat Rev Cancer 7(9):645-658. (Pubitemid 47327410)
7. Politi K, Pao W (2011) How genetically engineered mouse tumor models provide insights into human cancers. J Clin Oncol 29(16):2273-2281.
8. Johnson JI, et al. (2001) Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 84(10):1424-1431. (Pubitemid 32522115)
9. Voskoglou-Nomikos T, Pater JL, Seymour L (2003) Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 9(11):4227-4239. (Pubitemid 37204044)
10. Sacco MG, et al. (2000) Liposome-delivered angiostatin strongly inhibits tumor growth and metastatization in a transgenic model of spontaneous breast cancer. Cancer Res 60(10):2660-2665. (Pubitemid 30318241)
11. Hamzah J, et al. (2009) Targeted liposomal delivery of TLR9 ligands activates spontaneous antitumor immunity in an autochthonous cancer model. J Immunol 183(2): 1091-1098.
12. Wicki A, et al. (2012) Targeting tumor-associated endothelial cells: Anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth. Clin Cancer Res 18(2):454-464.
13. Sengupta P, et al. (2012) Cholesterol-tethered platinum II-based supramolecular nanoparticle increases antitumor efficacy and reduces nephrotoxicity. Proc Natl Acad Sci USA 109(28):11294-11299.
14. Huang Y-H, et al. (2009) Nanoparticle-delivered suicide gene therapy effectively reduces ovarian tumor burden in mice. Cancer Res 69(15):6184-6191.
15. Tanaka E, Choi HS, Fujii H, Bawendi MG, Frangioni JV (2006) Image-guided oncologic surgery using invisible light: Completed pre-clinical development for sentinel lymph node mapping. Ann Surg Oncol 13(12):1671-1681. (Pubitemid 44951476)
16. Veiseh O, et al. (2009) Specific targeting of brain tumors with an optical/magnetic resonance imaging nanoprobe across the blood-brain barrier. Cancer Res 69(15):6200-6207.
17. Olson ES, et al. (2010) Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases. Proc Natl Acad Sci USA 107(9):4311-4316.
18. Daldrup-Link HE, et al. (2011) MRI of tumor-associated macrophages with clinically applicable iron oxide nanoparticles. Clin Cancer Res 17(17):5695-5704.
19. Mikhaylov G, et al. (2011) Ferri-liposomes as an MRI-visible drug-delivery system for targeting tumours and their microenvironment. Nat Nanotechnol 6(9):594-602.
20. Nishiyama N, Kataoka K (2006) Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharmacol Ther 112(3):630-648. (Pubitemid 44592613)
21. Matsumura Y, Kataoka K (2009) Preclinical and clinical studies of anticancer agentincorporating polymer micelles. Cancer Sci 100(4):572-579.
22. Plummer R, et al. (2011) A Phase I clinical study of cisplatin- incorporated polymeric micelles (NC-6004) in patients with solid tumours. Br J Cancer 104(4):593-598.
23. Cabral H, Nishiyama N, Okazaki S, Koyama H, Kataoka K (2005) Preparation and biological properties of dichloro(1,2-diaminocyclohexane)platinum(II) (DACHPt)-loaded polymeric micelles. J Control Release 101(1-3):223-232. (Pubitemid 39600985)
24. Cabral H, Nishiyama N, Kataoka K (2007) Optimization of (1,2-diamino-cyclohexane) platinum(II)-loaded polymeric micelles directed to improved tumor targeting and enhanced antitumor activity. J Control Release 121(3):146-155. (Pubitemid 47212536)
25. Murakami M, et al. (2011) Improving drug potency and efficacy by nanocarrier-mediated subcellular targeting. Sci Transl Med 3(64):64ra2.
26. Cabral H, et al. (2011) Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol 6(12):815-823.
27. Rafi M, et al. (2012) Polymeric micelles incorporating (1,2-diaminocyclohexane)platinum (II) suppress the growth of orthotopic scirrhous gastric tumors and their lymph node metastasis. J Control Release 159(2):189-196.
28. American Cancer Society (2011) Cancer Facts & Figures 2011 (American Cancer Society, Atlanta).
29. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60(5):277-300.
30. Zhang N, Lyons S, Lim E, Lassota P (2009) A spontaneous acinar cell carcinoma model for monitoring progression of pancreatic lesions and response to treatment through noninvasive bioluminescence imaging. Clin Cancer Res 15(15):4915-4924.
31. Ornitz DM, Hammer RE, Messing A, Palmiter RD, Brinster RL (1987) Pancreatic neoplasia induced by SV40 T-antigen expression in acinar cells of transgenic mice. Science 238(4824):188-193. (Pubitemid 17139719)
32. Longnecker DS, Kuhlmann ET, Freeman DH, Jr. (1990) Characterization of the elastase 1-simian virus 40 T-antigen mouse model of pancreatic carcinoma: Effects of sex and diet. Cancer Res 50(23):7552-7554.
33. Tevethia MJ, Bonneau RH, Griffith JW, Mylin L (1997) A simian virus 40 large T-antigen segment containing amino acids 1 to 127 and expressed under the control of the rat elastase-1 promoter produces pancreatic acinar carcinomas in transgenic mice. J Virol 71(11):8157-8166. (Pubitemid 27446391)
34. Graham MA, et al. (2000) Clinical pharmacokinetics of oxaliplatin: A critical review. Clin Cancer Res 6(4):1205-1218. (Pubitemid 30226200)
35. Pasetto LM, D'Andrea MR, Rossi E, Monfardini S (2006) Oxaliplatin-related neurotoxicity: How and why? Crit Rev Oncol Hematol 59(2):159-168. (Pubitemid 44094106)
36. Ling B, Authier N, Balayssac D, Eschalier A, Coudore F (2007) Behavioral and pharmacological description of oxaliplatin-induced painful neuropathy in rat. Pain 128(3):225-234. (Pubitemid 46389544)
37. Duffy MJ, et al. (2010) Tumor markers in pancreatic cancer: A European Group on Tumor Markers (EGTM) status report. Ann Oncol 21(3):441-447.
38. Esteban-Fernández D, Verdaguer JM, Ramírez-Camacho R, Palacios MA, Gómez-Gómez MM (2008) Accumulation, fractionation, and analysis of platinum in toxicologically affected tissues after cisplatin, oxaliplatin, and carboplatin administration. J Anal Toxicol 32(2):140-146.
39. Vignot S, Faivre S, Aguirre D, Raymond E (2005) mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 16(4):525-537. (Pubitemid 40613318)
40. Kano MR, et al. (2007) Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-β signaling. Proc Natl Acad Sci USA 104(9):3460-3465. (Pubitemid 46364181)
41. Zhang L, Nishihara H, Kano MR (2012) Pericyte-coverage of human tumor vasculature and nanoparticle permeability. Biol Pharm Bull 35(5):761-766.
42. Trédan O, Galmarini CM, Patel K, Tannock IF (2007) Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 99(19):1441-1454.
43. Minchinton AI, Tannock IF (2006) Drug penetration in solid tumours. Nat Rev Cancer 6(8):583-592. (Pubitemid 44140857)
44. Yasunaga M, Manabe S, Matsumura Y (2011) New concept of cytotoxic immunoconjugate therapy targeting cancer-induced fibrin clots. Cancer Sci 102(7):1396-1402.
45. Nishida K, Yonemura K, Abe Y, Takagi K (1995) Antitumor effects of liposomes containing adriamycin on chemically-induced rat malignant fibrous histiocytoma. Nippon Seikeigeka Gakkai Zasshi 69(5):322-331.
46. Yazawa K, et al. (2001) Bifidobacterium longum as a delivery system for gene therapy of chemically induced rat mammary tumors. Breast Cancer Res Treat 66(2):165-170. (Pubitemid 32521423)
47. Nishiyama N, et al. (2003) Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice. Cancer Res 63(24):8977-8983. (Pubitemid 38064079)
48. Daly WH, Poche D (1988) The preparation of N-carboxyanhydrides of a-amino acids using bis(trichloromethyl)carbonate. Tetrahedron Lett 29(46):5859-5862.
49. Heinemann V, Haas M, Boeck S (2012) Systemic treatment of advanced pancreatic cancer. Cancer Treat Rev 38(7):843-853.
50. Schlom J, et al. (1992) Therapeutic advantage of high-affinity anticarcinoma radioimmunoconjugates. Cancer Res 52(5):1067-1072.
51. Cao C, et al. (2006) Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer. Cancer Res 66(23):11409-11415. (Pubitemid 46009972)
52. Terada Y, et al. (2004) Construction and commissioning of BL37XU at SPring-8. AIP Conf Proc 705(1):376-379.